CN103495142A - Chinese medicine soup for treating gastroesophageal reflus disease - Google Patents
Chinese medicine soup for treating gastroesophageal reflus disease Download PDFInfo
- Publication number
- CN103495142A CN103495142A CN201310473871.0A CN201310473871A CN103495142A CN 103495142 A CN103495142 A CN 103495142A CN 201310473871 A CN201310473871 A CN 201310473871A CN 103495142 A CN103495142 A CN 103495142A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- disease
- treatment
- medicine soup
- reflus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to the field of herbal formulas, and particularly relates to a Chinese medicine soup for treating a gastroesophageal reflus disease. The Chinese medicine soup is characterized by comprising the following raw materials by weight percent: 5-11% of pericarpium citri reticulatae, 8-14% of toosendan fruit, 5-11% of radix ophiopogonis, 5-11% of ginger, 8-14% of radix paeoniae alba, 5-11% of fevervine, 5-11% of rhizoma corydalis, 6-12% of flowers carthami, 6-12% of rhizoma corydalis, 6-12% of jasmine, 5-9% of white atractylodes rhizome, 8-14% of herba patriniae, 8-14% of chrysanthemum, and 6-12% of immature bitter orange. The raw medicinal materials s are soaked by water, and then filtrate is obtained after decoction and then deslagging. The Chinese medicine soup is low in cost, and free of obvious toxic and side effects; the gastroesophageal reflus disease can be effectively treated; the used medicinal materials can promote bowel peristalsis, can increase bowel tensity and reduce backflow, and has anti-inflammation and detoxification effects. Thus, a better curative effect can be obtained.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine preparation, specifically a kind of Chinese medicine decoction for the treatment of the gastroesophageal reflux sexually transmitted disease (STD).
Background technology
As everyone knows, reflux esophagitis (hereinafter to be referred as RE) is a kind of gastroesophageal reflux disease, by harmonization of the stomach duodenum content, be mainly that acidic gastric juice or acidic gastric juice add the pathological changes such as inflammation, erosion, ulcer and fibrosis of bile reflux to the caused mucous membrane of esophagus of esophagus.Many with symptoms such as heartburn, acid regurgitation, regurgitation, chest pains clinically, can repeatedly show effect, protracted course of disease, had a strong impact on patient's quality of life.This disease is in the past very common in western countries, but China's sickness rate increases gradually in recent years, and sickness rate increases with the age, and replacing gradually gastric and duodenal ulcers becomes gastrointestinal disease occurred frequently.Serious RE can cause the Barrett esophagus, and the latter is the precancerous lesion of adenocarcinoma of esophagus, and the incidence rate calibration ordinary person of its adenocarcinoma is high 30～50 times.For RE, the key of western medicine is press down acid and promote gastrointestinal peristalsis at present, prevents that gastric acid from backflowing, thereby eliminates the paathogenic factor that causes esophagitis.But esophagitis is owing to the excessively anti-stream of gastric juice, rather than the excessive secretion of gastric juice, and pressing down the acid treatment therefore long-term has the tendency of bringing out atrophic gastritis, and inactive antisecretory easily recurs, thereby it is significant to inquire into treatment by Chinese herbs.This disease is from the angle analysis of Chinese medicine, and its pathogenesis always belongs to stomach-QI being unable to descend normally, adverse rising of stomach-QI, and weakness of the spleen and stomach, liver-QI transversely invading the stomach, abnormal ascending-descending of QI, deficiency of stomach-Yin causes morbidity, the taste abnormal ascending-descending of QI causes anti-stream.
Summary of the invention
Purpose of the present invention is exactly in order to overcome above-mentioned existing technical deficiency, a kind of Chinese medicine decoction for the treatment of the gastroesophageal reflux sexually transmitted disease (STD) is provided, and cost is low, without obvious toxic-side effects, can effectively treat the reflux esophagitis disease, eliminate patient's misery, obviously improve patient's quality of life.Medicine used both can promote intestinal tube to wriggle, and can make again the intestinal tube tensity increase, and minimizing is backflowed, and the effect of antiinflammatory, removing toxic substances is arranged, therefore can receive good therapeutic effect.
The technical scheme that the present invention solves the problems of the technologies described above employing is: a kind of Chinese medicine decoction for the treatment of the gastroesophageal reflux sexually transmitted disease (STD), it is characterized in that, raw material forms: Pericarpium Citri Reticulatae 5～11, Fructus Toosendan 8～14, Radix Ophiopogonis 5～11, Rhizoma Zingiberis Recens 5～11, the Radix Paeoniae Alba 8～14, fevervine 5～11, Rhizoma Corydalis 5～11, Flos Carthami 6～12, Rhizoma Corydalis 6～12, Fructus Gardeniae 6～12, the Rhizoma Atractylodis Macrocephalae 5～9, Herba Patriniae 8～14, Flos Chrysanthemi 8～14, long-pending real 6～12, by the medicinal water soaking of above-mentioned raw materials, the filtrate of removing slag to obtain after decocting.
The invention has the beneficial effects as follows, cost is low, without obvious toxic-side effects, can effectively treat the reflux esophagitis disease, eliminate patient's misery, obviously improve patient's quality of life, medicine used both can promote intestinal tube to wriggle, can make again the intestinal tube tensity increase, minimizing is backflowed, and the effect of antiinflammatory, removing toxic substances is arranged, therefore can receive good therapeutic effect.
The specific embodiment
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1:
Adopt Pericarpium Citri Reticulatae, Fructus Toosendan, Radix Ophiopogonis, Rhizoma Zingiberis Recens, the Radix Paeoniae Alba, fevervine, Rhizoma Corydalis, Flos Carthami, Rhizoma Corydalis, Fructus Gardeniae, the Rhizoma Atractylodis Macrocephalae, Herba Patriniae, Flos Chrysanthemi, long-pending real in raw material is prepared from, the every clothes of its component (% by weight) are Pericarpium Citri Reticulatae 6, Fructus Toosendan 8, Radix Ophiopogonis 6, Rhizoma Zingiberis Recens 6, the Radix Paeoniae Alba 8, fevervine 6, Rhizoma Corydalis 6, Flos Carthami 7, Rhizoma Corydalis 7, Fructus Gardeniae 8, the Rhizoma Atractylodis Macrocephalae 6, Herba Patriniae 9, Flos Chrysanthemi 9, long-pending real 8.Get above-mentioned 14 kinds of raw material gross weights, 180 grams and mix, soak 1 hour by clean water, water consumption 1200ml, after intense fire is fried open, use slow fire boiling instead, extracting juice 200ml, two decoct and add water 300ml, decocting extracting juice 200ml, two decoct mixing, then decoct and be concentrated into 300ml, the sterile vacuum packing, and preparation gets product.Every day potion divide 2 times oral, each (medicine) being taken before meal 150ml sooner or later.
Its pathogenesis of the present invention always belongs to stomach-QI being unable to descend normally, adverse rising of stomach-QI, and weakness of the spleen and stomach, liver-QI transversely invading the stomach, abnormal ascending-descending of QI, deficiency of stomach-Yin causes morbidity, the taste abnormal ascending-descending of QI causes anti-stream.Control suitable pungent drugs can disperse and bitter drugs can descend, regulating the stomach and sending down the abnormal ascending QI, and sending down the abnormal ascending QI antacid through treatment all the time.Pericarpium Citri Reticulatae regulating qi-flowing for strengthening spleen in side, in tune, dampness, reduce phlegm.Cure mainly the distension and fullness in the abdomen of stagnation of QI in spleen and stomach or pain, dyspepsia.Abdominal distention uncomfortable in chest, indigestion and loss of appetite loose stool in the turbid damp resistance.Phlegm-damp is stopped up the cough and asthma of lung.Deficiency of vital energy body is dry, deficiency of YIN cough caused by dryness; Fructus Toosendan is slightly poisonous. and the property of medicine is cold, bitter in the mouth. and effect is promoting the circulation of QI to relieve pain, soothing the liver purging heat, parasite killing is treated tinea; Radix Ophiopogonis YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.For dryness of the lung dry cough, deficiency of YIN consumptive disease is coughed, the sore throat pharyngalgia, and Tianjin wound is thirsty, and interior-heat is quenched one's thirst, vexed insomnia, dryness of the intestine constipation; Rhizoma Zingiberis Recens dispels the wind, induces sweat, stomach function regulating, antalgic.Obviously analgesic, antibiotic, antiinflammation is arranged, calmness, emesis, antiallergic, antiplatelet aggregative activity are arranged; Radix Paeoniae Alba nourishing blood to suppress the hyperactive liver, slow middle pain relieving, yin fluid astringing is received antiperspirant.Control the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, leukorrhagia; The fevervine expelling wind and removing dampness, analgesic antidotal, promoting digestion and removing stagnation, promoting blood circulation and detumescence.The leukopenia caused for bones and muscles pain due to rheumatism, traumatic injury, traumatic pain, liver and gall and gastrointestinal angor, dyspepsia, infantile malnutrition, bronchus fire, radiation reaction; Rhizoma Corydalis is hot, bitter, temperature.Return liver, spleen channel.Invigorate blood circulation, promoting the circulation of QI, pain relieving.For the breast side of body, epigastric pain, amenorrhea dysmenorrhea, postpartum stagnation; Flos Carthami invigorate blood circulation latus rectum, eliminating stasis to stop pain.For amenorrhea, dysmenorrhea, lochia, lump in the abdomen mass in the abdomen, traumatic injury; Rhizoma Corydalis meridian distribution of property and flavor: acrid, bitter, warm.Return liver, spleen, heart channel.Effect: invigorate blood circulation, circulation of qi promoting, pain relieving.Application: be mainly used in blood stasis gas; Fructus Gardeniae pathogenic fire purging relieving restlessness, clearing away heat-damp and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body, main effect is vexed for calentura, gloomy, dry disturb not peaceful, dampness-heat in the liver and gallbladder pent-up; The Rhizoma Atractylodis Macrocephalae has invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive effect.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement; The key medicine of Herba Patriniae heat-clearing and toxic substances removing, removing blood stasis and expelling pus, the person who has rendered outstanding service for the treatment of lung abscess, acute appendicitis.The suppurative dermatosis such as treatment folliculitis, furuncle; Flos Chrysanthemi heat clearing away ability is strong, is usually used in loose wind heat, if get angry, oral ulcer, with its soaked can relieving inflammation or internal heat.Function with wind-dispelling heat-dissipating, nourishing the liver to improve visual acuity, refreshing and detoxicating; Long-pending reality cures mainly the dispelling the stagnated QI removing food stagnancy, reduces phlegm except painful abdominal mass.In main stagnating, stop, the feeling of fullness distending pain, constipation, heavy after dysentery, blocked-up chest, gastroptosis, uterine prolapse, proctoptosis.
But each raw material of the present invention embodiment that also the listed ratio of according to the form below (percentage by weight) is mixed realizes, it decocts program, oral methods is identical with embodiment 1, and its content is as shown in the table.
Below in conjunction with my institute, the clinical preliminary test that In Shandong Weihai central hospital carries out is done further, is described in detail the present invention:
1, establish observation group:
Select case 120 examples of observing, be the outpatient.Be divided at random treatment group and matched group with the precedence of going to a doctor, learn by statistics processing for two groups, in sex, on the age, equal not statistically significant.
2, clinical data:
1. treatment group 60 examples.Sex: male's 16 examples, women's 14 examples.Age: 28-45 year, average 35.8 years old.
2. matched group 60 examples.Sex: male's 14 examples, women's 16 examples.Age: 30-46 year, average 35.6 years old.
3, Therapeutic Method:
(1) treatment group: the oral Chinese medicine decoction, 150ml, bid, 7 days be a course for the treatment of.
(2) matched group: oral 1. motor activation regulator: cisapride 5～10mg, tid.2. acid inhibitor: cimetidine 400mg, bid, proton pump inhibitor omeprazole 20mg for the severe esophagitis, qd.3. mucosa protective agent: sucralfate suspension 10ml, tid.
4, observation index:
1. clinical symptoms: according to description, the mental status and the appetite of patient's subjective symptoms, appetite etc., by the doctor, carry out analysis-by-synthesis, judgement.Can be divided into healing, produce effects, effective, invalid four ranks.
2. Esophageal Mucosa situation under mirror: adopt Los Angeles staging.Can be divided into healing, produce effects, effective, invalid four ranks.
5, efficacy evaluation:
1. clinical symptoms standard: according to description, the mental status and the appetite of patient's subjective symptoms, appetite etc., by the doctor, carry out analysis-by-synthesis, judgement.
Cure: clinical symptom disappearance, without symptoms such as heartburn, acid regurgitation, regurgitation, chest pains;
Produce effects: clinical symptoms is obviously improved, and the symptom such as heartburn, acid regurgitation, regurgitation, chest pain is obviously alleviated;
Effectively: clinical symptoms is improved, and the symptoms such as heartburn, acid regurgitation, regurgitation, chest pain are alleviated to some extent;
Invalid: clinical symptoms is without improvement, before the symptom such as heartburn, acid regurgitation, regurgitation, chest pain and medication without significant change
2. scope standard: adopt Los Angeles staging.
Normally: Esophageal Mucosa does not have breakage
A level (one or more Esophageal Mucosa breakages, major diameter is less than 5mm);
B level (one or more mucosa breakages, major diameter is greater than 5mm, but there is no the amalgamation pathological changes);
C level (the mucosa breakage has fusion, but is less than 75% esophagus Zhou Jing);
D level (Esophageal Mucosa merges, and at least reaches 75% esophagus Zhou Jing).
3. curative effect judging standard
Cure: clinical symptom disappearance, Esophageal Mucosa pathological changes disappearance (Histological change is not counted in interior) under scope.
Produce effects: clinical symptoms is obviously improved, and under scope, the mucosa pathological changes alleviates at least 2 ranks.
Effectively: clinical symptoms is improved, and under scope, the mucosa pathological changes alleviates 1-2 rank.
Invalid: clinical symptoms is without improvement, and under scope, the unchanged or pathological changes of mucosa pathological changes alleviates less than 1 rank or occurs worsening.
Therapeutic outcome:
Treat 8 weeks clinical symptoms for two groups and improve situation in Table 1, under scope, the Esophageal Mucosa situation of change is in Table 2; After 6 months, clinical symptoms is improved situation in Table 3, and under scope, the Esophageal Mucosa situation of change is in Table 4; After 1 year, clinical symptoms is improved situation in Table 5, and under scope, the Esophageal Mucosa situation of change is in Table 6.
Table 1 liang group treatment clinical symptoms improvement situation after 8 weeks
* total effective rate refers to the ratio of the effective number of cases of this group internal therapy and total number of cases; Effectively number of cases refers to " healing ", " produce effects ", " effectively " sum, relative with engineering noise.Following table all with.
χ
2＝4.39，P＜0.05。
By table 1 result, can be found out: two groups for the treatment of RE are all effective, but treatment group is used normalizing the stomach by guiding QI downward soup curative effect better, and two groups of contrasts have statistical significance.
Table 2 liang group treatment 8 weeks is Esophageal Mucosa situation of change under mirror afterwards
χ
2＝5.29，P＜0.05。
By table 2 result, can be found out: during two groups for the treatment of RE, under mirror, the Esophageal Mucosa extent of damage all alleviates to some extent, but treatment group is improved, the reparation situation is better, and two groups of contrasts have statistical significance.
Table 3 liang group treatment clinical symptoms improvement situation after 6 months
χ
2＝58.95，P＜0.001；
By table 3 result, can be found out: RE is effective in the treatment group treatment; Treatment of control group RE is invalid, approximately 88.3% case recurrence
[2].Two groups of contrasts have significant difference, therefore think that normalizing the stomach by guiding QI downward soup treatment RE late result is good, effective prevention of recurrence.
Table 4 liang group treatment Esophageal Mucosa situation of change under mirror after 6 months
χ
2＝55.19，P＜0.001；
By table 4 result, can be found out: the Microscopic observation Esophageal Mucosa, RE is effective in the treatment group treatment.Treatment of control group RE is invalid, and approximately 93.33% case Esophageal Mucosa does not improve, repairs.Two groups of contrasts have significant difference, therefore think that normalizing the stomach by guiding QI downward soup treatment RE late result is good, effective prevention of recurrence.
Table 5 liang group treatment clinical symptoms improvement situation after 1 year
χ
2＝66.35，P＜0.001；
By table 5 result, can be found out: RE is effective in the treatment group treatment; Treatment of control group RE is invalid, 100% case recurrence, and related symptoms occurs again.Two groups of contrasts have significant difference, therefore think that normalizing the stomach by guiding QI downward soup treatment RE late result is good, effective prevention of recurrence.
Table 6 liang group treatment Esophageal Mucosa situation of change under mirror after 1 year
▲ some patients were adheres to not doing the gastroscope check with examining, therefore this group sum reduces.
χ
2＝36，P＜0.001。
By table 6 result, can be found out: the Microscopic observation Esophageal Mucosa, RE is effective in the treatment group treatment.Treatment of control group RE is invalid, and 100% case Esophageal Mucosa does not improve, repairs.Two groups of contrasts have significant difference, therefore think that normalizing the stomach by guiding QI downward soup treatment RE late result is good, effective prevention of recurrence.
Conclusion: short term efficacy and the late result for the treatment of group treatment RE all are better than matched group, and significant difference is arranged.
6, side effect:
The clinical apparent side effect that has no for the treatment of group, the matched group omeprazole has certain irritation to stomach.
Claims (1)
1. a Chinese medicine decoction for the treatment of the gastroesophageal reflux sexually transmitted disease (STD), it is characterized in that: the raw material composition is by weight percentage, Pericarpium Citri Reticulatae 5～11, Fructus Toosendan 8～14, Radix Ophiopogonis 5～11, Rhizoma Zingiberis Recens 5～11, the Radix Paeoniae Alba 8～14, fevervine 5～11, Rhizoma Corydalis 5～11, Flos Carthami 6～12, Rhizoma Corydalis 6～12, Fructus Gardeniae 6～12, the Rhizoma Atractylodis Macrocephalae 5～9, Herba Patriniae 8～14, Flos Chrysanthemi 8～14, long-pending real 6～12, by the medicinal water soaking of above-mentioned raw materials, the filtrate of removing slag to obtain after decocting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310473871.0A CN103495142A (en) | 2013-09-24 | 2013-09-24 | Chinese medicine soup for treating gastroesophageal reflus disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310473871.0A CN103495142A (en) | 2013-09-24 | 2013-09-24 | Chinese medicine soup for treating gastroesophageal reflus disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103495142A true CN103495142A (en) | 2014-01-08 |
Family
ID=49860463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310473871.0A Pending CN103495142A (en) | 2013-09-24 | 2013-09-24 | Chinese medicine soup for treating gastroesophageal reflus disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103495142A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491590A (en) * | 2014-11-26 | 2015-04-08 | 山东永泰化工有限公司 | Health-care tea used for gastroesophageal reflux cough |
| CN105055812A (en) * | 2015-07-31 | 2015-11-18 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating gastroesophageal reflux disease with syndrome of heat stagnation in liver and stomach |
| CN105535479A (en) * | 2015-12-28 | 2016-05-04 | 天长市中医院 | Shenshao stomach benefiting composition and application thereof |
| CN105617215A (en) * | 2016-03-02 | 2016-06-01 | 金丽丽 | Medicine for treating reflux esophagitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829310A (en) * | 2010-05-06 | 2010-09-15 | 杜山鹏 | Traditional Chinese medicine preparation for treating reflux esophagitis |
-
2013
- 2013-09-24 CN CN201310473871.0A patent/CN103495142A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829310A (en) * | 2010-05-06 | 2010-09-15 | 杜山鹏 | Traditional Chinese medicine preparation for treating reflux esophagitis |
Non-Patent Citations (3)
| Title |
|---|
| 吴沛田: "败酱草治疗胃食管反流病", 《中医杂志》 * |
| 张保国: "《方剂现代新解》", 31 January 2011 * |
| 李乾构: "达立通颗粒治疗胃食管反流病的研究", 《中华中医药学会脾胃病分会第二十三次全国脾胃病学术交流会论文汇编》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491590A (en) * | 2014-11-26 | 2015-04-08 | 山东永泰化工有限公司 | Health-care tea used for gastroesophageal reflux cough |
| CN105055812A (en) * | 2015-07-31 | 2015-11-18 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating gastroesophageal reflux disease with syndrome of heat stagnation in liver and stomach |
| CN105535479A (en) * | 2015-12-28 | 2016-05-04 | 天长市中医院 | Shenshao stomach benefiting composition and application thereof |
| CN105617215A (en) * | 2016-03-02 | 2016-06-01 | 金丽丽 | Medicine for treating reflux esophagitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1321680C (en) | Chinese medicine composition for treating gastritis, gastric ulcer and duodenal ulcer | |
| CN101829310B (en) | Traditional Chinese medicine preparation for treating reflux esophagitis | |
| CN103356973B (en) | Antineoplastic traditional Chinese medicine | |
| CN102908606B (en) | Traditional Chinese medicine for treating pregnancy vomiting | |
| CN102920820A (en) | Traditional Chinese medicine composition for treating chronic colitis | |
| CN103495142A (en) | Chinese medicine soup for treating gastroesophageal reflus disease | |
| CN101450149B (en) | Medicine for treating abdominal postoperative stomach palsy syndrome and preparation method | |
| CN100548367C (en) | A kind of Chinese medicine composition of took orally for treating chronic gastritis | |
| CN102526670A (en) | Traditional Chinese medicinal composition for treating cholecystitis and preparation method thereof | |
| CN104288745A (en) | Traditional Chinese medicine for treating CG (Chronic Gastritis) | |
| CN104258369A (en) | Traditional Chinese medicine composition for treating epigastric pain | |
| CN101780220B (en) | Traditional Chinese medicine for treating chronic gastritis | |
| CN104740042A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis | |
| CN103768451B (en) | The Chinese medicine for the treatment of chronic pancreatitis | |
| CN103638280B (en) | For treating the Chinese medicine of reflux esophagitis | |
| CN105267593A (en) | Traditional Chinese medicine with effect of reducing blood fat | |
| CN101780259B (en) | Traditional Chinese medicine for treating gastric cancer | |
| CN101559205A (en) | Traditional Chinese medicine composition for curing chronic gastritis | |
| CN101095872A (en) | Chinese traditional medicine composition for treating anaphylactoid purpura nephritis | |
| CN104383403A (en) | Traditional Chinese medicinal composition for treating chronic gastritis | |
| CN102626498B (en) | Qianlingchijin decoction for treating chronic pancreatitis | |
| CN101204482B (en) | Peroral Chinese traditional medicine compositte for gastric ulcer | |
| CN105853882A (en) | Medicine for treating stomach illness and preparation method | |
| CN103656412A (en) | Traditional Chinese medicine decoction for treating measles | |
| CN106038887A (en) | Traditional Chinese medicine for treating stomach disease with middle-jiao cold and dampness and upper-jiao fire syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140108 |
|
| WD01 | Invention patent application deemed withdrawn after publication |